GlassScriptPhysician profile
Imelda Tio
NPI 1053404830
$4,473.39
in general payments reported to CMS, 2019-2025
23 companies · $396 in 2025
The $396 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $500 · 2021: $939 · 2022: $1,030 · 2023: $848 · 2024: $100 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.55 |
| Education | $100.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,208.15 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Pfizer INC. | $518.03 | 2019-2024 | |
| Avion Pharmaceuticals | $359.87 | 2019-2023 | Balcoltra |
| Exeltis, USA INC. | $305.39 | 2021-2025 | Slynd, Solosec |
| Therapeuticsmd, INC. | $262.35 | 2019-2022 | |
| Astellas Pharma US INC | $231.61 | 2019-2025 | Veozah, Xospata |
| Allergan, INC. | $227.99 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $218.23 | 2021-2025 | |
| Evofem Biosciences, INC. | $187.93 | 2021-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $150.06 | 2021-2022 | |
| Coopersurgical, INC. | $119.26 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $111.89 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $92.00 | 2019 | |
| Hologic Sales and Service, LLC | $87.44 | 2022-2025 | Thinprep 2000 Processor, Aptima |
| Millicent US INC | $86.78 | 2024-2025 | Intrarosa, Femring, Femlyv |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $86.28 | 2023-2025 | Myfembree |
| Agile Therapeutics, INC. | $53.95 | 2021-2023 | Twirla |
| Duchesnay USA Incorporated | $48.48 | 2019 | |
| Exact Sciences Corporation | $34.25 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $31.20 | 2023 | Accrufer |
| Organon LLC | $22.96 | 2021 | |
| Lupin INC. | $17.24 | 2019 | |
| Merck Sharp & Dohme LLC | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imelda Tio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.